Gyre Therapeutics subsidiary submits NDA in China for F351 for CHB-induced liver fibrosis

GYRE THERAPEUTICS, INC.

Gyre's majority-owned subsidiary Gyre Pharmaceuticals submitted NDA to China's CDE for lead candidate F351 (Hydronidone).
F351 is for treatment of chronic hepatitis B (CHB)-induced liver fibrosis.
NDA subject to formatting verification; CDE will issue acceptance number before technical review.
Company will work with CDE on supplementary materials if requested.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.